Porphyromonas gingivalis-dendritic cell interactions: Consequences for coronary artery disease

Journal of Oral Microbiology

Volumn 2, Issue 2010, 2010, Pages

  Zeituni, Amir E ^a   Carrion, Julio ^a   Cutler, Christopher W ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Dc sign; Dendritic cells; Periodontitis; Porphyromonas gingivalis

Indexed keywords

EID: 84555164232     PISSN: None     EISSN: 20002297     Source Type: Journal    
DOI: 10.3402/jom.v2i0.5782     Document Type: Article

References (93)

1. Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol 2010; 8: 481-90.
2. Pathirana RD, O'Brien-Simpson NM, Reynolds EC. Host immune responses to Porphyromonas gingivalis antigens. Periodontol 2000 2010; 52: 218-37.
3. Rylev M, Kilian M. Prevalence and distribution of principal periodontal pathogens worldwide. J Clin Periodontol 2008; 35: 346-61.
4. Ximenez-Fyvie LA, Haffajee AD, Socransky SS. Comparison of the microbiota of supra- and subgingival plaque in health and periodontitis. J Clin Periodontol 2000; 27: 648-57.
5. Zeituni AE, Jotwani R, Carrion J, Cutler CW. Targeting of DC-SIGN on human dendritic cells by minor fimbriated Porphyromonas gingivalis strains elicits a distinct effector T cell response. J Immunol 2009; 183: 5694-704.
6. Zeituni AE, McCaig W, Scisci E, Thanassi DG, Cutler CW. Native 67 kDa minor fimbriae of Porphyromonas gingivalis: a novel glycoprotein with DC-SIGN-targeting motifs. J Bacteriol 2010; 192(16): 4103-10.
7. Burt B. Position paper: epidemiology of periodontal diseases. J Periodontol 2005; 76: 1406-19.
8. Gibson FC III, Hong C, Chou HH, Yumoto H, Chen J, Lien E, et al. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 2801-6.
9. Reddy MS. Reaching a better understanding of non-oral disease and the implication of periodontal infections. Periodontol 2000 2007; 44: 9-14.
10. Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001; 68: 160-6.
11. Cutler CW Jr. Dendritic cells at the oral mucosal interface. J Dent Res 2006; 85: 678-89.
12. Velazquez JR, Teran LM. Chemokines and their receptors in the allergic airway inflammatory process. Clin Rev Allergy Immunol 2010 Mar 30 [Epub ahead on print].
13. Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005; 26: 1700-4.
14. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010; 134: 25-32.
15. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-61.
16. Cutler CW, Jotwani R. Dendritic cells at the oral mucosal interface. J Dent Res 2006; 85: 678-89.
17. Jotwani R, Cutler CW. Multiple dendritic cell (DC) subpopulations in human gingiva and association of mature DCs with CD4- T-cells in situ. J Dent Res 2003; 82: 736-41.
18. Bodineau A, Coulomb B, Tedesco AC, Seguier S. Increase of gingival matured dendritic cells number in elderly patients with chronic periodontitis. Arch Oral Biol 2009; 54: 12-6.
19. Jotwani R, Pulendran B, Agrawal S, Cutler CW. Human dendritic cells respond to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro. Eur J Immunol 2003; 33: 2980-6.
20. Jotwani R, Cutler CW. Fimbriated Porphyromonas gingivalis is more efficient than fimbria-deficient P. gingivalis in entering human dendritic cells in vitro and induces an inflammatory Th1 effector response. Infect Immun 2004; 72: 1725-32.
21. Igyarto BZ, Jenison MC, Dudda JC, Roers A, Muller W, Koni PA, et al. Langerhans cells suppress contact hypersensitivity responses via cognate CD4 interaction and langerhans cellderived IL-10. J Immunol 2009; 183: 5085-93.
22. Igyarto BZ, Kaplan DH. The evolving function of Langerhans cells in adaptive skin immunity. Immunol Cell Biol 2010; 88: 361-5.
23. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 2002; 16: 135-44.
24. Vita JA, Loscalzo J. Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium. Circulation 2002; 106: 164-6.
25. Gibson FC III, Yumoto H, Takahashi Y, Chou HH, Genco CA. Innate immune signaling and Porphyromonas gingivalis-accelerated atherosclerosis. J Dent Res 2006; 85: 106-21.
26. Rackley CE. Vascular abnormalities in the metabolic syndrome: mechanisms and therapy. Curr Atheroscler Rep 2005; 7: 403-4.
27. Erridge C. The roles of pathogen-associated molecular patterns in atherosclerosis. Trends Cardiovasc Med 2008; 18: 52-6.
28. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103: 1064-70.
29. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Victor A, et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke 2002; 33: 2581-6.
30. Celik T, Iyisoy A, Celik M, Isik E. The ongoing debate over the association between Chlamydia pneumoniae infection and coronary artery disease: antibiotic dilemma. Int J Cardiol 2008; 130: 260-2.
31. Aghajanian A, Wittchen ES, Allingham MJ, Garrett TA, Burridge K. Endothelial cell junctions and the regulation of vascular permeability and leukocyte transmigration. J Thromb Haemost 2008; 6(9): 1453-60.
32. O'Connor CM, DunneMW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459-66.
33. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646-54.
34. Capestany CA, Tribble GD, Maeda K, Demuth DR, Lamont RJ. Role of the Clp system in stress tolerance, biofilm formation, and intracellular invasion in Porphyromonas gingivalis. J Bacteriol 2008; 190: 1436-46.
35. Gibson FC III, Genco CA. Porphyromonas gingivalis mediated periodontal disease and atherosclerosis: disparate diseases with commonalities in pathogenesis through TLRs. Curr Pharm Des 2007; 13: 3665-75.
36. Eick S, Pfister W. Efficacy of antibiotics against periodontopathogenic bacteria within epithelial cells: an in vitro study. J Periodontol 2004; 75: 1327-34.
37. RAMS TM FD, editor. Occurrence of Clindamycin-resistant Porphyromonas gingivalis in Human Periodontitis. San Antonio, TX: International Association for Dental Research; 2003.
38. Kozarov EV, Dorn BR, Shelburne CE, DunnWA Jr., Progulske-Fox A. Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Arterioscler Thromb Vasc Biol 2005; 25: e17-e18.
39. Kaplan M, Yavuz SS, Cinar B, Koksal V, Kut MS, Yapici F et al. Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. Int J Infect Dis 2006; 10: 116-23.
40. Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci (Lond) 2008; 114: 509-31.
41. Lalla E, Lamster IB, Hofmann MA, Bucciarelli L, Jerud AP, Tucker S, et al. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2003; 23: 1405-11.
42. Pussinen PJ, Tuomisto K, Jousilahti P, Havulinna AS, Sundvall J, Salomaa V. Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arterioscler Thromb Vasc Biol 2007; 27: 1433-9.
43. Mustapha IZ, Debrey S, Oladubu M, Ugarte R. Markers of systemic bacterial exposure in periodontal disease and cardiovascular disease risk: a systematic review and meta-analysis. J Periodontol 2007; 78: 2289-302.
44. Bahekar AA, Singh S, Saha S, Molnar J, Arora R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. Am Heart J 2007; 154: 830-7.
45. Trichopoulou A, Yiannakouris N, Bamia C, Benetou V, Trichopoulos D, Ordovas JM. Genetic predisposition, nongenetic risk factors, and coronary infarct. Arch Intern Med 2008; 168: 891-6.
46. Austin MA, Rodriguez BL, McKnight B, McNeely MJ, Edwards KL, Curb JD, et al. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese- American men. Am J Cardiol 2000; 86: 412-6.
47. Loof TG, Rohde M, Chhatwal GS, Jung S, Medina E. The contribution of dendritic cells to host defenses against Streptococcus pyogenes. J Infect Dis 2007; 196: 1794-803.
48. MacIntyre A, Abramov R, Hammond CJ, Hudson AP, Arking EJ, Little CS, et al. Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells. J Neurosci Res 2003; 71: 740-50.
49. Greiffenberg L, Goebel W, Kim KS, Weiglein I, Bubert A, Engelbrecht F, et al. Interaction of Listeria monocytogenes with human brain microvascular endothelial cells: InlB-dependent invasion, long-term intracellular growth, and spread from macrophages to endothelial cells. Infect Immun 1998; 66: 5260-7.
50. Cutler CW, Kalmar JR, Genco CA. Pathogenic strategies of the oral anaerobe, Porphyromonas gingivalis. Trends Microbiol 1995; 3: 45-51.
51. Lamont RJ, Jenkinson HF. Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Microbiol Mol Biol Rev 1998; 62: 1244-63.
52. Imamura T, Travis J, Potempa J. The biphasic virulence activities of gingipains: activation and inactivation of host proteins. Curr Protein Pept Sci 2003; 4: 443-50.
53. Mezyk-Kopec R, Bzowska M, Potempa J, Jura N, Sroka A, Black RA, et al. Inactivation of membrane tumor necrosis factor alpha by gingipains from Porphyromonas gingivalis. Infect Immun 2005; 73: 1506-14.
54. Potempa J, Mikolajczyk-Pawlinska J, Brassell D, Nelson D, Thogersen IB, Enghild JJ, et al. Comparative properties of two cysteine proteinases (gingipains R), the products of two related but individual genes of Porphyromonas gingivalis. J Biol Chem 1998; 273: 21648-57.
55. Sroka A, Sztukowska M, Potempa J, Travis J, Genco CA. Degradation of host heme proteins by lysine- and argininespecific cysteine proteinases (gingipains) of Porphyromonas gingivalis. J Bacteriol 2001; 183: 5609-16.
56. Pulendran B, Kumar P, Cutler CW, Mohamadzadeh M, Van Dyke T, Banchereau J. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 2001; 167: 5067-76.
57. Hamada N, Sojar HT, Cho MI, Genco RJ. Isolation and characterization of a minor fimbria from Porphyromonas gingivalis. Infect Immun 1996; 64: 4788-94.
58. Arai M, Hamada N, Umemoto T. Purification and characterization of a novel secondary fimbrial protein from Porphyromonas gingivalis strain 381. FEMS Microbiol Lett 2000; 193: 75-81.
59. Xie H, Lamont RJ. Promoter architecture of the Porphyromonas gingivalis fimbrillin gene. Infect Immun 1999; 67: 3227-35.
60. Yilmaz O, Watanabe K, Lamont RJ. Involvement of integrins in fimbriae-mediated binding and invasion by Porphyromonas gingivalis. Cell Microbiol 2002; 4: 305-14.
61. Nakagawa I, Amano A, Kuboniwa M, Nakamura T, Kawabata S, Hamada S. Functional differences among FimA variants of Porphyromonas gingivalis and their effects on adhesion to and invasion of human epithelial cells. Infect Immun 2002; 70: 277-85.
62. Hajishengallis G, Harokopakis E. Porphyromonas gingivalis interactions with complement receptor 3 (CR3): innate immunity or immune evasion? Front Biosci 2007; 12: 4547-57.
63. Harokopakis E, Albzreh MH, Haase EM, Scannapieco FA, Hajishengallis G. Inhibition of proinflammatory activities of major periodontal pathogens by aqueous extracts from elder flower (Sambucus nigra). J Periodontol 2006; 77: 271-9.
64. Takeshita A, Murakami Y, Yamashita Y, Ishida M, Fujisawa S, Kitano S, et al. Porphyromonas gingivalis fimbriae use beta2 integrin (CD11/CD18) on mouse peritoneal macrophages as a cellular receptor, and the CD18 beta chain plays a functional role in fimbrial signaling. Infect Immun 1998; 66: 4056-60.
65. Feinberg H, Mitchell DA, Drickamer K, Weis WI. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001; 294: 2163-6.
66. Appelmelk BJ, van Die I, van Vliet SJ, Vandenbroucke-Grauls CM, Geijtenbeek TB, van Kooyk Y. Cutting edge: carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells. J Immunol 2003; 170: 1635-9.
67. Guo Y, Feinberg H, Conroy E, Mitchell DA, Alvarez R, Blixt O, et al. Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat Struct Mol Biol 2004; 11: 591-8.
68. Zhang P, Schwartz O, Pantelic M, Li G, Knazze Q, Nobile C et al. DC-SIGN (CD209) recognition of Neisseria gonorrhoeae is circumvented by lipooligosaccharide variation. J Leukoc Biol 2006; 79: 731-8.
69. Maeda N, Nigou J, Herrmann JL, Jackson M, Amara A, Lagrange PH, et al. The cell surface receptor DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan. J Biol Chem 2003; 278: 5513-6.
70. Soilleux EJ, Sarno EN, Hernandez MO, Moseley E, Horsley J, Lopes UG, et al. DC-SIGN association with the Th2 environment of lepromatous lesions: cause or effect? J Pathol 2006; 209: 182-9.
71. Pohlmann S, Baribaud F, Lee B, Leslie GJ, Sanchez MD, Hiebenthal-Millow K, et al. DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol 2001; 75: 4664-72.
72. Jotwani R, Palucka AK, Al-Quotub M, Nouri-Shirazi M, Kim J, Bell D, et al. Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. J Immunol 2001; 167: 4693-700.
73. Soilleux EJ, Morris LS, Trowsdale J, Coleman N, Boyle JJ. Human atherosclerotic plaques express DC-SIGN, a novel protein found on dendritic cells and macrophages. J Pathol 2002; 198: 511-6.
74. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-94.
75. Bobryshev YV, Lord RS. Expression of heat shock protein-70 by dendritic cells in the arterial intima and its potential significance in atherogenesis. J Vasc Surg 2002; 35: 368-75.
76. Cao W, Bobryshev YV, Lord RS, Oakley RE, Lee SH, Lu J. Dendritic cells in the arterial wall express C1q: potential significance in atherogenesis. Cardiovasc Res 2003; 60: 175-86.
77. Erbel C, Sato K, Meyer FB, Kopecky SL, Frye RL, Goronzy JJ, et al. Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol 2007; 102: 123-32.
78. Muzzio ML, Miksztowicz V, Brites F, Aguilar D, Repetto EM, Wikinski R, et al. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res 2009; 40: 48-53.
79. Jotwani R, Eswaran SV, Moonga S, Cutler CW. MMP-9/TIMP-1 imbalance induced in human dendritic cells by Porphyromonas gingivalis. FEMS Immunol Med Microbiol 2010; 58: 314-21.
80. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999; 107: 85-97.
81. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999; 147: 213-25.
82. Reape TJ, Rayner K, Manning CD, Gee AN, Barnette MS, Burnand KG, et al. Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques. Am J Pathol 1999; 154: 365-74.
83. Weber C, Schober A, Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1997-2008.
84. Pan S, Kleppe LS, Witt TA, Mueske CS, Simari RD. The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis. Thromb Haemost 2004; 92: 495-502.
85. Shi H, Ge J, Fang W, Yao K, Sun A, Huang R, et al. Peripheralblood dendritic cells in men with coronary heart disease. Am J Cardiol 2007; 100: 593-7.
86. Yilmaz A, Weber J, Cicha I, Stumpf C, Klein M, Raithel D, et al. Decrease in circulating myeloid dendritic cell precursors in coronary artery disease. J Am Coll Cardiol 2006; 48: 70-80.
87. Yilmaz A, Schaller T, Cicha I, Altendorf R, Stumpf C, Klinghammer L, et al. Predictive value of the decrease in circulating dendritic cell precursors in stable coronary artery disease. Clin Sci (Lond) 2009; 116: 353-63.
88. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
89. Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol 2002; 2: 77-84.
90. Engering A, Van Vliet SJ, Geijtenbeek TB, Van Kooyk Y. Subset of DC-SIGN(-) dendritic cells in human blood transmits HIV-1 to T lymphocytes. Blood 2002; 100: 1780-6.
91. Wu J, Lin X, Xie H. Porphyromonas gingivalis short fimbriae are regulated by a FimS/FimR two-component system. FEMS Microbiol Lett 2007; 271: 214-21.
92. Wu J, Lin X, Xie H. OxyR is involved in coordinate regulation of expression of fimA and sod genes in Porphyromonas gingivalis. FEMS Microbiol Lett 2008; 282: 188-95.
93. Li L, Michel R, Cohen J, Decarlo A, Kozarov E. Intracellular survival and vascular cell-to-cell transmission of Porphyromonas gingivalis. BMC Microbiol 2008; 8: 26-37.